{"context":{"query":">>chembl_molecule>>clinical_trials","source_dataset":"chembl_molecule","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]CHEMBL3707227,22,CHEMBL3707227,168,-1]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"CHEMBL3707227","source":"CHEMBL3707227|ATEZOLIZUMAB","targets":["NCT03285763|A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|COMPLETED|PHASE4|INTERVENTIONAL","NCT05185505|Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria|RECRUITING|PHASE4|INTERVENTIONAL","NCT05689671|Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma|RECRUITING|PHASE4|INTERVENTIONAL","NCT05717400|Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy|TERMINATED|PHASE4|INTERVENTIONAL","NCT06031233|Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie|RECRUITING|PHASE4|INTERVENTIONAL","NCT07059494|Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant|RECRUITING|PHASE4|INTERVENTIONAL","NCT01810913|Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT02008227|A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy|COMPLETED|PHASE3|INTERVENTIONAL","NCT02302807|A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]|COMPLETED|PHASE3|INTERVENTIONAL","NCT02366143|A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02367781|A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02367794|A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]|COMPLETED|PHASE3|INTERVENTIONAL","NCT02409342|A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]|COMPLETED|PHASE3|INTERVENTIONAL","NCT02409355|A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)|TERMINATED|PHASE3|INTERVENTIONAL","NCT02420821|A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02425891|A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02450331|A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection|TERMINATED|PHASE3|INTERVENTIONAL","NCT02486718|Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT02620280|Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1|COMPLETED|PHASE3|INTERVENTIONAL","NCT02657434|A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02763579|A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02788279|A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02807636|Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT02813785|A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy|COMPLETED|PHASE3|INTERVENTIONAL","NCT02839707|Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|ACTIVE_NOT_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT02891824|ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab|COMPLETED|PHASE3|INTERVENTIONAL","NCT02908672|A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT02912559|Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT02928406|A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract|COMPLETED|PHASE3|INTERVENTIONAL","NCT02997228|Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03016312|A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen|COMPLETED|PHASE3|INTERVENTIONAL","NCT03024996|A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy|TERMINATED|PHASE3|INTERVENTIONAL","NCT03038100|A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT03125902|A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)|COMPLETED|PHASE3|INTERVENTIONAL","NCT03148418|A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03178552|A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)|ACTIVE_NOT_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT03191786|A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy|COMPLETED|PHASE3|INTERVENTIONAL","NCT03197935|A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT03199885|Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT03273153|A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma|TERMINATED|PHASE3|INTERVENTIONAL","NCT03281954|Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03353831|Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT03371017|A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT03434379|A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT03452137|A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck|TERMINATED|PHASE3|INTERVENTIONAL","NCT03456063|A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)|COMPLETED|PHASE3|INTERVENTIONAL","NCT03498716|A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer|TERMINATED|PHASE3|INTERVENTIONAL","NCT03556839|Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03595592|Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03598270|Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT03603184|Atezolizumab Trial in Endometrial Cancer - AtTEnd|COMPLETED|PHASE3|INTERVENTIONAL","NCT03693573|A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT03726879|A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT03735121|A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT03755791|Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03762018|BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma|COMPLETED|PHASE3|INTERVENTIONAL","NCT03768063|A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03775265|Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03799835|Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03811002|Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03922997|A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT03977194|Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04028050|A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT04102098|A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04148911|A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT04177108|A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT04194203|A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)|COMPLETED|PHASE3|INTERVENTIONAL","NCT04214262|Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04256421|A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT04294810|A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT04338269|A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment|COMPLETED|PHASE3|INTERVENTIONAL","NCT04402788|Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT04446117|Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04471428|Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy|COMPLETED|PHASE3|INTERVENTIONAL","NCT04487067|A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista|COMPLETED|PHASE3|INTERVENTIONAL","NCT04513925|A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)|COMPLETED|PHASE3|INTERVENTIONAL","NCT04540211|A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT04543617|A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04619797|A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT04637594|Trying to Find the Correct Length of Treatment with Immune Checkpoint Therapy|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04649489|A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04660344|A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04665856|Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04712643|A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04732286|A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy|TERMINATED|PHASE3|INTERVENTIONAL","NCT04732598|A Phase III Study of Bevacizumab and Paclitaxel in Combination with Atezolizumab As a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04740918|A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)|TERMINATED|PHASE3|INTERVENTIONAL","NCT04770896|A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04803994|The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma|RECRUITING|PHASE3|INTERVENTIONAL","NCT04873362|A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05047250|A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05058651|Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT05063552|Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers|ACTIVE_NOT_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT05091567|A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05112965|An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05141721|A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer|ACTIVE_NOT_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT05224141|Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05317858|Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets|RECRUITING|PHASE3|INTERVENTIONAL","NCT05425940|Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05468489|To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL"]}]}